Drug utilisation study in hospitalised chronic kidney disease patients, using World Health Organisation prescribing indicators: an observational study.

Wadia S Alruqayb, Vibhu Paudyal, Price Malcolm, Asif Sarwar, Jeff Aston, Anthony R Cox
Author Information
  1. Wadia S Alruqayb: Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia. ORCID
  2. Vibhu Paudyal: Department of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. ORCID
  3. Price Malcolm: Department of Applied Health, Test Evaluation Research Group - University of Birmingham, Birmingham, UK. ORCID
  4. Asif Sarwar: Pharmacy Department, University Hospitals Birmingham NHS Foundation Trust - Heritage Building Queen Elizabeth Hospital - Queen Elizabeth Medical Centre, Birmingham, UK.
  5. Jeff Aston: Pharmacy Department, University Hospitals Birmingham NHS Foundation Trust - Heritage Building Queen Elizabeth Hospital - Queen Elizabeth Medical Centre, Birmingham, UK. ORCID
  6. Anthony R Cox: Department of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. ORCID

Abstract

Background: Chronic kidney disease (CKD) is associated with comorbidities and altered pharmacokinetics, making appropriate prescribing, and monitoring necessary to minimise drug-related problems (DRPs). Therefore, this study aimed to describe the drug-utilisation pattern in hospitalised CKD patients.
Methods: An observational study was conducted in hospitalised adult (≥18 years old) CKD patients in the UK using WHO prescribing indicators, from November 2021 to April 2022 in a large teaching hospital in England from admission until discharge. This study used STATA version 16 for analysis.
Results: The mean number of drugs per prescription was 11.1(±5), the percentage of encounters resulting in the prescription of an antibiotic was 62%, the percentage of drugs prescribed by generic name was 90%, the percentage of encounters resulting in the prescription of an injection was 94%, and the percentage of drugs prescribed from essential drugs list or formulary was 89%. The most frequent drug group prescribed Alimentary Tract and Metabolism was 22%. Longer hospital stays, admission to a renal ward, and the number of comorbidities were independently associated with polypharmacy.
Conclusion: Not all prescribing indicators evaluated in this study were in full compliance with WHO recommendations. Polypharmacy was found in most participants which might require interventions to avoid DRPs. Further research is needed to evaluate factors associated with prescribing in the CKD population and prescriber perspectives on decision-making in the context of available guidelines and patient factors.

Keywords

References

  1. Cochrane Database Syst Rev. 2018 Sep 03;9:CD008165 [PMID: 30175841]
  2. Drugs. 2019 Mar;79(4):365-379 [PMID: 30758803]
  3. J Bras Nefrol. 2014 Jan-Mar;36(1):26-34 [PMID: 24676611]
  4. BMC Geriatr. 2020 Mar 4;20(1):87 [PMID: 32131742]
  5. Clin Interv Aging. 2008;3(2):383-9 [PMID: 18686760]
  6. Eur J Clin Pharmacol. 2017 Sep;73(9):1187-1194 [PMID: 28634642]
  7. Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1085-1095 [PMID: 29934432]
  8. Clin Transl Sci. 2021 Nov;14(6):2242-2253 [PMID: 34080321]
  9. J Am Acad Nurse Pract. 2005 Apr;17(4):123-32 [PMID: 15819637]
  10. Saudi Pharm J. 2016 Mar;24(2):189-96 [PMID: 27013912]
  11. JAMA Intern Med. 2015 May;175(5):827-34 [PMID: 25798731]
  12. Med Mal Infect. 2020 Jun;50(4):323-331 [PMID: 31326299]
  13. WHO Reg Publ Eur Ser. 1993;45:183-91 [PMID: 8442846]
  14. Drug Saf. 2021 Oct;44(10):1041-1058 [PMID: 34510389]
  15. J Am Med Dir Assoc. 2015 Jun 1;16(6):535.e1-12 [PMID: 25869992]
  16. Curr Opin Nephrol Hypertens. 2011 Sep;20(5):492-7 [PMID: 21788893]
  17. Pharmacoecon Open. 2020 Mar;4(1):27-36 [PMID: 31218653]
  18. Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1080-1090 [PMID: 30862698]
  19. Res Social Adm Pharm. 2015 May-Jun;11(3):468-71 [PMID: 25280463]
  20. Drug Saf. 2016 Feb;39(2):109-16 [PMID: 26692396]
  21. Clin Pharmacol. 2017 Oct 26;9:125-132 [PMID: 29123429]
  22. Indian J Pharmacol. 2014 Jan-Feb;46(1):35-9 [PMID: 24550582]
  23. Saudi J Kidney Dis Transpl. 2012 Mar;23(2):403-8 [PMID: 22382249]
  24. Lancet. 2017 Mar 25;389(10075):1238-1252 [PMID: 27887750]
  25. Clin Kidney J. 2019 May 24;12(5):663-672 [PMID: 31584562]
  26. Clin Kidney J. 2019 Jun 17;12(5):659-662 [PMID: 31584570]
  27. Perspect Clin Res. 2020 Apr-Jun;11(2):70-74 [PMID: 32670831]
  28. J Pharmacol Pharmacother. 2016 Jan-Mar;7(1):51-4 [PMID: 27127400]
  29. BMC Health Serv Res. 2013 May 07;13:170 [PMID: 23647871]
  30. BMC Nephrol. 2016 Jul 26;17:96 [PMID: 27456700]

Word Cloud

Created with Highcharts 10.0.0prescribingstudyCKDdrugspercentagekidneydiseaseassociatedhospitalisedpatientsWHOindicatorsprescriptionprescribedChroniccomorbiditiesDRPspatternobservationalusinghospitaladmissionnumberencountersresultingdrugfactorsutilisationBackground:alteredpharmacokineticsmakingappropriatemonitoringnecessaryminimisedrug-relatedproblemsThereforeaimeddescribedrug-utilisationMethods:conductedadult≥18yearsoldUKNovember2021April2022largeteachingEnglanddischargeusedSTATAversion16analysisResults:meanper111±5antibiotic62%genericname90%injection94%essentiallistformulary89%frequentgroupAlimentaryTractMetabolism22%LongerstaysrenalwardindependentlypolypharmacyConclusion:evaluatedfullcompliancerecommendationsPolypharmacyfoundparticipantsmightrequireinterventionsavoidresearchneededevaluatepopulationprescriberperspectivesdecision-makingcontextavailableguidelinespatientDrugchronicWorldHealthOrganisationindicators:

Similar Articles

Cited By